195 related articles for article (PubMed ID: 26286294)
21. Novel ametantrone-amsacrine related hybrids as topoisomerase IIβ poisons and cytotoxic agents.
Zagotto G; Gianoncelli A; Sissi C; Marzano C; Gandin V; Pasquale R; Capranico G; Ribaudo G; Palumbo M
Arch Pharm (Weinheim); 2014 Oct; 347(10):728-37. PubMed ID: 25042690
[TBL] [Abstract][Full Text] [Related]
22. Relationship between expression of topoisomerase II isoforms and chemosensitivity in choroidal melanoma.
Satherley K; de Souza L; Neale MH; Alexander RA; Myatt N; Foss AJ; Hungerford JL; Hickson ID; Cree IA
J Pathol; 2000 Oct; 192(2):174-81. PubMed ID: 11004693
[TBL] [Abstract][Full Text] [Related]
23. The role of pixantrone in the treatment of non-Hodgkin's lymphoma.
Borchmann P; Schnell R
Expert Opin Investig Drugs; 2005 Aug; 14(8):1055-61. PubMed ID: 16050797
[TBL] [Abstract][Full Text] [Related]
24. Mitoxantrone-Surfactant Interactions: A Physicochemical Overview.
Enache M; Toader AM; Enache MI
Molecules; 2016 Oct; 21(10):. PubMed ID: 27754390
[TBL] [Abstract][Full Text] [Related]
25. Deciphering molecular aspects of interaction between anticancer drug mitoxantrone and tRNA.
Ray B; Agarwal S; Kadian H; Gambhir K; Sharma P; Mehrotra R
J Biomol Struct Dyn; 2017 Aug; 35(10):2090-2102. PubMed ID: 27686178
[TBL] [Abstract][Full Text] [Related]
26. DNA topoisomerase II inhibitors.
IARC Monogr Eval Carcinog Risks Hum; 2000; 76():175-344. PubMed ID: 11000976
[No Abstract] [Full Text] [Related]
27. Topoisomerase as target for antibacterial and anticancer drug discovery.
Kathiravan MK; Khilare MM; Nikoomanesh K; Chothe AS; Jain KS
J Enzyme Inhib Med Chem; 2013 Jun; 28(3):419-35. PubMed ID: 22380774
[TBL] [Abstract][Full Text] [Related]
28. DNA topoisomerase II-dependent cytotoxicity of alkylaminoanthraquinones and their N-oxides.
Smith PJ; Blunt NJ; Desnoyers R; Giles Y; Patterson LH
Cancer Chemother Pharmacol; 1997; 39(5):455-61. PubMed ID: 9054961
[TBL] [Abstract][Full Text] [Related]
29. Evaluation of the in vitro cytotoxicity of mitoxantrone following repeated freeze-thaw cycles.
Mauldin GN; Truax R
Vet Ther; 2002; 3(3):290-6. PubMed ID: 12447837
[TBL] [Abstract][Full Text] [Related]
30. A novel epoxypropoxy flavonoid derivative and topoisomerase II inhibitor, MHY336, induces apoptosis in prostate cancer cells.
Patra N; De U; Kang JA; Kim JM; Ahn MY; Lee J; Jung JH; Chung HY; Moon HR; Kim HS
Eur J Pharmacol; 2011 May; 658(2-3):98-107. PubMed ID: 21376033
[TBL] [Abstract][Full Text] [Related]
31. Indenoindolone derivatives as topoisomerase II-inhibiting anticancer agents.
Kashyap M; Kandekar S; Baviskar AT; Das D; Preet R; Mohapatra P; Satapathy SR; Siddharth S; Guchhait SK; Kundu CN; Banerjee UC
Bioorg Med Chem Lett; 2013 Feb; 23(4):934-8. PubMed ID: 23321564
[TBL] [Abstract][Full Text] [Related]
32. Synergistic interaction between histone deacetylase and topoisomerase II inhibitors is mediated through topoisomerase IIbeta.
Marchion DC; Bicaku E; Turner JG; Daud AI; Sullivan DM; Munster PN
Clin Cancer Res; 2005 Dec; 11(23):8467-75. PubMed ID: 16322310
[TBL] [Abstract][Full Text] [Related]
33. A rational design strategy of the novel topoisomerase II inhibitors for the synthesis of the 4-O-(2-pyrazinecarboxylic)-4'-demethylepipodophyllotoxin with antitumor activity by diminishing the relaxation reaction of topoisomerase II-DNA decatenation.
Zhao W; Chen L; Li HM; Wang DJ; Li DS; Chen T; Yuan ZP; Tang YJ
Bioorg Med Chem; 2014 Jun; 22(11):2998-3007. PubMed ID: 24775914
[TBL] [Abstract][Full Text] [Related]
34. Increased cellular accumulation and distribution of amrubicin contribute to its activity in anthracycline-resistant cancer cells.
Mamidipudi V; Shi T; Brady H; Surapaneni S; Chopra R; Aukerman SL; Heise C; Sung V
Cancer Chemother Pharmacol; 2012 Apr; 69(4):965-76. PubMed ID: 22120960
[TBL] [Abstract][Full Text] [Related]
35. Synthesis and biological activity of ferrocenyl indeno[1,2-c]isoquinolines as topoisomerase II inhibitors.
Wambang N; Schifano-Faux N; Aillerie A; Baldeyrou B; Jacquet C; Bal-Mahieu C; Bousquet T; Pellegrini S; Ndifon PT; Meignan S; Goossens JF; Lansiaux A; Pélinski L
Bioorg Med Chem; 2016 Feb; 24(4):651-60. PubMed ID: 26740155
[TBL] [Abstract][Full Text] [Related]
36. Selective cellular uptake and retention of SN 28049, a new DNA-binding topoisomerase II-directed antitumor agent.
Chen YY; Lukka PB; Joseph WR; Finlay GJ; Paxton JW; McKeage MJ; Baguley BC
Cancer Chemother Pharmacol; 2014 Jul; 74(1):25-35. PubMed ID: 24801172
[TBL] [Abstract][Full Text] [Related]
37. Mitoxantrone: its development and role in clinical practice.
Weiss RB
Oncology (Williston Park); 1989 Jun; 3(6):135-41; discussion 141-3, 147-8. PubMed ID: 2701571
[TBL] [Abstract][Full Text] [Related]
38. Synthesis, cytotoxicity, DNA interaction, and topoisomerase II inhibition properties of novel indeno[2,1-c]quinolin-7-one and indeno[1,2-c]isoquinolin-5,11-dione derivatives.
Ryckebusch A; Garcin D; Lansiaux A; Goossens JF; Baldeyrou B; Houssin R; Bailly C; Hénichart JP
J Med Chem; 2008 Jun; 51(12):3617-29. PubMed ID: 18507368
[TBL] [Abstract][Full Text] [Related]
39. Sequence selectivity of topoisomerase II DNA cleavage stimulated by mitoxantrone derivatives: relationships to drug DNA binding and cellular effects.
De Isabella P; Capranico G; Palumbo M; Sissi C; Krapcho AP; Zunino F
Mol Pharmacol; 1993 May; 43(5):715-21. PubMed ID: 8388987
[TBL] [Abstract][Full Text] [Related]
40. Cytotoxicity and topoisomerase I/II inhibition activity of novel 4-aryl/alkyl-1-(piperidin-4-yl)-carbonylthiosemicarbazides and 4-benzoylthiosemicarbazides.
Siwek A; Bielawska A; Maciorkowska E; Lepiarczyk M; Bielawski K; Trotsko N; Wujec M
J Enzyme Inhib Med Chem; 2014 Apr; 29(2):243-8. PubMed ID: 23432612
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
